Zenabis Global has received the licensing of Phase 2C – Part 1 at Zenabis Atholville (an additional 9,800 kg of licensed annual cultivation capacity). Additionally, the company has received a cultivation license from Health Canada for Zenabis Langley.
Andrew Grieve, Chief Executive Officer of Zenabis, stated, “We would like to express our gratitude to the communities of northern New Brunswick that supported us from 2015 through to substantial completion, including the Listuguj First Nation, an initial equity investor in our business. We would also like to express our gratitude to the Province of New Brunswick for investing in our business, and to the people of New Brunswick for making us the number one selling recreational cannabis company in this province.
"Personally, I would like to thank every member of the construction and licensing teams for their exceptional effort in completing this asset. We believe that the efficient approval of the Phase 2C – Part 1 license amendment is a testament to the outstanding quality of our construction and licensing teams."
"We look forward to the cultivation team delivering well above the design capacity of this asset in accordance with recent performance. Zenabis has now increased its licensed capacity nearly six-fold since the creation of the company in January of 2019 through the business combination of Sun Pharm Investments Ltd. and Bevo Agro Inc. We intend to deliver on our commitment to more than quadruple capacity again in the near-term with the licensing and completion of our Zenabis Langley initial conversion.”
Zenabis Langley features a highly advanced production environment that supports both growing and packaging operations for both bulk and retail products. Zenabis Langley will employ more than 200 staff after Site A is complete. Leveraging a closed greenhouse system, cultivation techniques from Zenabis Atholville, and extensive cultivation automation, the Company expects Zenabis Langley to achieve a product quality comparable to that of output from Zenabis Atholville, an indoor facility, at a cultivation cost per gram of $0.75 or less.
Andrew Grieve, Chief Executive Officer of Zenabis, stated, “We are pleased to receive this cultivation license, which increases our licensed annual cultivation capacity by nearly one third. Year-to-date, we have increased our licensed annual cultivation capacity more than eight-fold on a design capacity basis, which excludes our consistent, and consistently increasing, outperformance. Of additional note, we believe that the receipt of the Zenabis Langley cultivation license in less than one month from the point of submission is a testament to both the quality of our facilities and the strength of our regulatory team.”
“On behalf of everyone at Zenabis, I would like to thank the community of Langley for supporting us, our licensing and construction teams, the contractors, and the service providers that made this milestone possible,” continued Mr. Grieve.